Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01602406
Title Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

stomach cancer

Her2-receptor positive breast cancer

Therapies

Elgemtumab + Trastuzumab

Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | BEL


No variant requirements are available.